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It has been suggested that the effect of implanted cells on the local environment is important when selecting the
appropriate cell type for tissue regeneration. Our aim was to compare the local tissue response to implanted
human mesenchymal stem cells (MSC) and human umbilical vein endothelial cells (EC). MSC and EC were
cultured in poly(l-lactide-co-1,5-dioxepan-2-one) scaffolds for 1 week in a bioreactor system, after which they
were implanted subcutaneously in NOD/SCID mice. After 3 weeks, scaffolds were retrieved, and the mRNA
expression of selected genes involved in hypoxia and inflammation was examined by real-time reverse tran-
scription polymerase chain reaction and correlated with immunofluorescent staining for corresponding proteins.
The Toll-like receptor signaling pathway was examined by superarray hybridization. The expression of 53
angiogenesis-related proteins was investigated by a proteome profiler angiogenesis antibody array kit. Vas-
cularization was quantified using immunohistochemistry for CD31. The expression of hypoxia-inducible factors
and biomarkers for angiogenesis was more strongly upregulated in response to implanted EC than to MSC,
suggesting a higher sensitivity to low oxygen tension among EC. Hypoxic signaling was increased after
implantation of EC compared with MSC, leading to a prolonged acute inflammatory phase that promoted
ingrowth of vascular cells and establishment of the circulation. Inflammatory cytokines were also differently
expressed at the gene and protein levels in the two experimental groups, resulting in altered recruitment of acute
and chronic inflammatory cells. The end result of these differences was increased vessel formation within the
constructs in the EC group.
Introduction
For vascular tissue engineering, as well as in re-generation of parenchymal tissue, such as muscle or
bone, extensive efforts have been made to learn how to
generate functional vascular supply for implanted cells.
These efforts have been made based on the premise that
implanted cells cannot survive, differentiate, and regenerate
lost tissue without an immediate functional blood supply. In
situations where the circulation has been compromised, cell
therapy has been explored with the aim of re-establishing
circulation to regenerate the damaged tissue. Hematopoietic
stem cells have demonstrated cardiomyogenic potential after
implantation in ischemic cardiac tissue,1 and endothelial
progenitor cells have been the subjects of extensive research
efforts for their potential in cardiovascular regeneration.2
Bone marrow mesenchymal stem cells (MSC) are the
most widely applied cells in cell therapy due to their
availability and differentiation potential. The interaction
between MSC and vascular cells has been extensively ex-
plored, and MSC have diverse roles in the vascularization of
tissue through either direct contact or indirect signaling. The
autocrine and paracrine effects of MSC initiate release of
cytokines, growth factors, and extracellular matrix pro-
teins.3,4 In an attempt to generate functional vessels that can
be connected with the local circulation after implantation,
coculture systems have been used with vascular cells grown
with supporting cells, such as smooth muscle cells (SMC) or
MSC.5–7
The proliferation and maturation of endothelial cells (EC)
and surrounding matrix depend on local oxygen supply8,9
and the crosstalk between EC and immune cells, which
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results in release of cytokines and chemokines.10 The direct
contribution of implanted vascular or MSC to tissue re-
generation is not well described in most studies, although
both cell types contribute to development and repair of the
majority of the body tissues. Several authors have suggested
that the favorable effect of implanting cells or bioactive
molecules on regeneration in a damaged area is as much the
result of creating a favorable microenvironment for cell
migration and proliferation as it is of direct deposition of
extracellular matrix components by the implanted cells.11,12
It is clear, however, that the basis for healthy tissue is a
functional circulation, which in turn applies to both paren-
chymal and vascular tissue engineering. All implanted cells
are exposed to a hypoxic environment after implantation due
to the acute inflammation following the surgical procedure,
as well as the initial absence of blood vessels. The cellular
response to hypoxia is therefore a key in facilitating an
adequate postoperative inflammatory reaction and the es-
tablishment of a functional blood supply. These cellular
events are closely connected to each other and crucial for
ensuring vital and healthy tissue regeneration.
Based on this, our hypothesis was that MSC and EC re-
spond differently to the hypoxic environment created when
cells are implanted in vivo and that the inflammatory re-
sponse as well as the establishment of the blood supply are
different between the two cell types. The aims of the study
therefore were first to compare the effect of implanting MSC
and EC on the expression of inflammatory cytokines and
the migration of acute and chronic inflammatory cells and
second to compare the effect of implanted cells on expres-
sion of vascular factors and development of the circulation.
Materials and Methods
Fabrication of scaffolds
Poly(l-Lactide-co-1,5-dioxepan-2-one) [poly (LLA-co-
DXO)] was synthesized, and scaffolds were prepared as
previously described.13,14 Briefly, a solvent casting/particulate
leaching method was used to produce poly (LLA-co-DXO)
porous scaffolds with pore sizes of 90–500 mm, 12 mm di-
ameter, and 1.5 mm thick. The sterilization of scaffolds was
carried out in a pulsed electron accelerator operating at 6.5
MeV (Mikrotron, Acceleratorteknik, The Royal Institute
of Technology, Stockholm, Sweden), with radiation of 2.5
Mrad dose in an inert atmosphere.
Cell culture
Primary human MSC were purchased from StemCell
Technologies. Flow cytometry was done to confirm the
purity of the cells, >90% of the cells expressed CD29,
CD44, CD105, and CD166 and <1% expressed CD14, CD34,
and CD45. The MSC were cultured in MesenCult complete
medium (StemCell Technologies) following the manufac-
turer’s instructions.
Human umbilical vein EC were purchased from Lonza
(Clonetics). They were expanded in endothelial cell growth
medium (EGM) (Lonza) containing 500 mL endothelial cell
basal medium and supplements, 10 mL fetal bovine serum,
2 mL bovine brain extract, 0.5 mL human endothelial growth
factor, 0.5 mL hydrocortisone, and 0.5 mL GA-1000. The
MSC and EC were cultured at 37C and 5% CO2 and were
used between passages 2 and 5.
In vivo implantation
The scaffolds were preseeded with cells before in vivo
implantation and were treated as previously described.7,15
Briefly, the scaffolds were divided into two groups: MSC and
EC, prewet with respective complete medium and incubated
overnight at 37C and 5% CO2. In total, 5 · 105 cells were
seeded per scaffold in each group. An orbital shaker (Ep-
pendorf) was used to facilitate homogeneous distribution of
cells. The scaffolds loaded with cells were kept in an incu-
bator overnight to allow cell attachment. The following day,
scaffolds were transferred to separate modified spinner flasks
(Wheaton Science) for 1 week in a dynamic culture system
with 50 rpm. After 1-week in vitro culture, 6-mm discs were
punctured from the center of the scaffold with a dermal skin
puncher and then implanted in vivo. For evaluating seeding
efficiency of MSC and EC, the cells were seeded in scaffold
as described above, and after 1 h, the scaffolds were removed
from the wells, and unattached cells were counted by an
Automated Cell Counter (Invitrogen). Cell seeding efficiency
was calculated by the following equation16:
Cell seeding efficiency%
¼

1 number of unattached cells
number of seeded cells

· 100
The animal experiments were approved by the Norwegian
Animal Research Authority and conducted according to the
European Convention for the Protection of Vertebrates used
for Scientific Purposes (local approval no. 3029). Nonobese
diabetic/severe combined immunodeficient (NOD/SCID)
mice (n = 15) were purchased from Taconic Farms (Bom-
holtgård Breeding and Research Center). The animals were
kept in polystyrene cages containing wood shavings in a
climate-controlled environment with 12-h dark–12-h light
cycles and fed with standard rodent chow and water ad
libitum. Animals were 6–8 weeks old at the time of surgery.
The animals were anesthetized with an intramuscular in-
jection of 20mL of Rompun (xylazine) (20 mg/mL) (Bayer
Healthcare) and Narketan (ketamine) (Vétoquinol) in 1:2
ratio. On the back of the mice, a 2.5-cm incision was made,
providing sufficient space for subcutaneous implantation of
scaffolds. A scaffold for each experimental group (MSC or
EC) was placed in the mouse, with a total of six mice used
for each time point. Wounds were closed with Vetbond
Tissue Adhesive (n-butyl cyanoacrylate) (3M). After 3-
week implantation, animals were euthanized with deep
isoflurane (Schering Plough) anesthesia, followed by cer-
vical dislocation, after which the implanted scaffolds were
carefully dissected and retrieved. The samples were then
divided and further processed either for real-time reverse
transcription polymerase chain reaction (RT–PCR) analysis
and western blotting or for histological embedding.
Real-time RT–PCR
E.Z.N.A. Total RNA Kit (Omega Bio-Tek) was used to
isolate the RNA from the samples. Quantifications and de-
termination of RNA purity were performed with a Nano-
Drop Spectrophotometer (Thermo Scientific NanoDrop
Technologies). A high-capacity cDNA Archive Kit (Applied
Biosystems) was used for the reverse transcription reaction.
Total RNA (1000 ng) was mixed with nuclease-free water,
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reverse transcriptase buffer, random primers, dNTP, and
MultiScribe reverse transcriptase. Standard enzyme and cy-
cling conditions were applied for 2 min at 50C and 20 s at
95C, followed by 1 s at 95C and 20 s at 60C per cycle (40
cycles). cDNA corresponding to 10 ng mRNA in each reac-
tion was prepared in duplicate since the standard deviation
between the duplicates was minimal for each target gene.
Real-time RT–PCR was performed on a StepOnePlus Real-
Time PCR System (Applied Biosystems). Mouse-specific
TaqMan gene expression assays (Applied Biosystems) were
used to evaluate postimplanted constructs. The preimplanted
constructs were also assessed to evaluate baseline expression
of inflammatory and hypoxic markers. For this, human-
specific TaqMan gene expression assays (Applied Biosystems)
were used. Data analysis was performed with a comparative
Ct method, with GAPDH as endogenous control.17
Superarray analysis was performed for the mouse
Toll-like receptor (TLR) pathway Rt2 Profiler PCR Arrays
(SuperArray Bioscience). Rt2 PCR Array First Strand Kit
(SuperArray Bioscience) was used for cDNA synthesis.
PCR was done on a StepOnePlus Real-Time PCR System
(Applied Biosystems) with Rt2 Real-Time SyBR Green/Rox
PCR Mix (SuperArray Bioscience).
Immunofluorescent staining
The remaining half of the sample was immediately embedded
in optimal cutting temperature compound (Tissue-Tek O.C.T.;
Sakura Finetek) and kept at -80C. Eight-micrometer-thick
cryosectioning was done with Leica CM3050 S (Leica Micro-
systems) at -24C. Sections were obtained from the middle part
of the scaffolds and were used for immunostaining. Sections
from 3-week samples were incubated with primary antibodies
in blocking buffer overnight at 4C and with secondary an-
tibodies for 2 h the following day. The nuclei were counter-
stained with DAPI (1:1000) for 2 min, and the slides were
mounted with ProLong Gold Antifade Reagent (Invitrogen)
before imaging. Rabbit polyclonal anti-mouse interleukin
(IL)-1b (Abcam), rat monoclonal anti-mouse neutrophil
(NIMP) (Abcam), rabbit polyclonal anti-mouse IL-6 (Ab-
cam), rat monoclonal anti-mouse CD11b (BD Biosciences),
and rat monoclonal anti-mouse CD31 (BD Biosciences) were
used as primary antibodies. Goat anti-rabbit FITC (Santa
Cruz Biotechnology) and Alexa Fluor 546 goat anti-rat (In-
vitrogen) were used as secondary antibodies. Double staining
with IL-1b and NIMP was performed to identify the number
of IL-1b-positive cells and the number of neutrophils, re-
spectively. Double staining with IL-6 and CD11b was per-
formed to colocalize macrophages or monocyte-derived cells
and their production of IL-6. CD31 staining was performed to
allow determination of the total area fraction of vessels.
Quantification of immunostaining
Five sections from one scaffold were mounted on each
slide. Each section on the slides was divided into five mea-
suring grids starting from top to bottom in the vertical di-
rection. Five sections on each slide (average for the mouse)
and five measuring grids in each section (average for the
section) were used for image quantification. Images were
taken with a Zeiss AxioVision 4.8.1 at 10· magnification, and
the files were exported as JPEG standard. The measuring
grids in each section were noted carefully to avoid any
overlap while taking the images. In each section, the areas
with no cells were excluded. NIS Elements AR 3.2 software
was used for quantifications. First, the threshold was defined
for each channel: red, green, and blue. Next, to avoid mis-
interpretation, all the channels were simultaneously referred
before counting the cells. The blue channel was referred
continuously to visualize the nuclei, and then, the counting
was done in the red and green channels separately. Finally,
colocalized cells were counted for red and green fluorescent
staining together. The number of counted cells was exported
to a Microsoft Excel (Microsoft Corporation) file before
statistical analysis was performed. For quantification of CD31
immunostaining, images were taken at 20· magnification,
and the total area fraction of vessel was quantified.
Western blotting
Protein extraction was performed following the protocol
of Chomczynski.18 Briefly, isopropanol was added to the
organic phase (extracted during RNA isolation) for protein
precipitation. Precipitate was washed with ethanol and dis-
solved in 0.5% sodium dodecyl sulfate (SDS) solution.
NanoDrop Spectrophotometer (Thermo Scientific Nano-
Drop Technologies) was used to quantify and determine
protein purity. A total of 30 mg protein was mixed with
4 · Laemmli sample buffer (Bio-Rad Laboratories) and
loaded on 4–15% Mini-PROTEAN TGX Precast Gel
(Bio-Rad) for electrophoresis. Transfer was done with
PVDF transfer membranes (TRANS-Blot Turbo System;
Bio-Rad). The membranes were blocked overnight at 4C
and incubated the next day with primary antibodies (Santa
Cruz): anti-mouse hypoxia-inducible factor 1-alpha (HIF-
1a), anti-mouse aryl hydrocarbon receptor nuclear translo-
cator (ARNT), and anti-mouse GAPDH in blocking buffer
overnight at 4C and the following day with secondary an-
tibody: horseradish peroxidase-conjugated goat anti-rabbit
IgG (Bio-Rad) for 1 h. Immunoblotting bands were visual-
ized by Immun-Star WesternC Chemiluminescence
Kits, and a Gel Doc EZ System (Bio-Rad) was used for
imaging and protein-band assay.
Proteome profiling
The Mouse Angiogenesis Array (R&D Systems, Inc.) was
used to detect the expression of 53 angiogenesis-related
proteins in the experimental groups. These Proteome Pro-
filer Arrays were handled according to the manufactur-
er’s protocol. Briefly, the protein extraction was done, and
100 mg of total protein was mixed with a cocktail of bioti-
nylated detection antibodies and then incubated with a ni-
trocellulose membrane spotted with capture antibodies in
duplicate. Protein detection antibodies bound to the cap-
ture antibody were detected using streptavidin–HRP and
chemiluminescent detection reagents. The Gel Doc EZ
System (Bio-Rad) was used for imaging. The mean spot
pixel density was quantified using image software analysis.
Statistical analyses
SPSS Statistics 21 (IBM) was applied for statistical pro-
cessing and analysis. Two groups, MSC and EC, were
compared with the independent samples t-test. The signifi-
cance level was set to p < 0.05 for all statistical analyses,
with n = 6 for each group.
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Results
Alteration in the TLR pathway
The evaluation of genes related to the mouse TLR path-
way showed that 49 genes were downregulated and 35 genes
were upregulated, with a fold change more than one in the
EC group compared with the MSC group (Fig. 1A, B).
Release of inflammatory cytokines
Inflammation was evaluated through the release of pro-
and anti-inflammatory cytokines. RT–PCR (human-specific
genes) of preimplanted constructs showed higher mRNA
expression of the genes encoding IL-1b and IL-10 in the
MSC group, whereas the expression of the gene IL-6 was
similar in both groups (not shown). RT–PCR for mouse-
specific genes was performed after 3 weeks of implantation.
Decreased mRNA expression of the genes enconding the
proinflammatory cytokines, IL-1b and IL-6, was observed in
EC constructs ( p < 0.05) (Fig. 2B, C). However, the mRNA
expression of the gene encoding the anti-inflammatory cy-
tokine IL-10 was upregulated in EC constructs compared
with MSC constructs ( p < 0.01) (Fig. 2D).
Inflammatory cell recruitment
The acute and chronic inflammatory cell recruitment was
evaluated by immunofluorescence staining and systematic
FIG. 1. Alteration in the
Toll-like receptor (TLR)
signaling pathway. (A) Rt2
Profiler TLR signaling
polymerase chain reaction
(PCR) array following 3
weeks of implantation
in vivo. Heat maps re-
presenting the relative ex-
pression levels of all genes
involved in the mouse TLR
signaling pathway. In-
creased and decreased fold
changes in endothelial cell
(EC) constructs compared
with mesenchymal stem
cell (MSC) constructs are
represented by red and
green squares, respectively.
(B) Gene layout of heat
maps and data are presented
as *p < 0.05, **p < 0.01.
Color images available
online at www.liebertpub
.com/tea
FIG. 2. Real-time reverse transcription (RT)–PCR for mouse-specific genes after 3 weeks of implantation in vivo. Relative
gene expression of the genes encoding the inflammatory cytokines (A) tumor necrosis factor-alpha (TNFa), (B) interleukin-1-
beta (IL-1b), (C) IL-6, and (D) IL-10 comparing MSC and EC constructs. Data presented as mean – standard deviation (n = 6).
*p < 0.05, **p < 0.01.
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quantification. Cells stained positive with antineutrophil
antibody were found scattered all over the constructs, pre-
dominantly in the EC group (Fig. 3A) ( p < 0.01). Fewer IL-
1b-positive cells were seen in the EC group than in the MSC
group ( p < 0.01) (Fig. 3C). Double staining for monocyte-
derived cells (CD11b) and IL-6 showed fewer positive cells
in the EC group, but this difference was not statistically
significant (Fig. 3C). Cells stained positive with CD11b and
IL-6 were found in close proximity to the scaffold and may
have aided in the degradation process (Fig. 3B).
Cellular response to a hypoxic environment
To evaluate the response to hypoxia after implantation,
the mRNA expression of the genes encoding HIF-1a and
ARNT was analyzed. Both markers were significantly up-
regulated in EC constructs after 3 weeks of implantation
(Fig. 4A, B). On the contrary, western blotting showed
lower protein level of HIF-1a in EC constructs, while the
protein level of ARNT was higher in EC constructs com-
pared with MSC constructs (Fig. 4E). The mRNA expres-
sion of the gene encoding mTOR was significantly
upregulated in the EC group (Fig. 4D). The mRNA ex-
pression of the genes encoding human HIF-1a and ARNT
was significantly higher in the EC group before implantation
compared to the MSC group.
Angiogenic properties of MSC and EC
To evaluate the angiogenic properties of the cells after 3
weeks of implantation, proteome profiling was done
(Fig. 5A). The histogram generated after the mean spot pixel
density quantification revealed that of the 53 related proteins
for angiogenesis, 10 proteins were highly regulated. The
proteins related to vascular development were higher in the
EC group compared with the MSC group (Fig. 5B). In ad-
dition, the total area fraction of vessel formation was
quantified to determine the influence of implanted cells on
establishment of the vasculature. The EC constructs had a
higher density of blood vessel formation, as evaluated by
CD31 immunostaining, and the total vessel area fraction
was significantly higher ( p < 0.01) (Fig. 5C).
FIG. 3. Inflammatory cell
recruitment to tissue-
engineered constructs after
3 weeks of implantation
in vivo. (A) Neutrophil
transmigration to the con-
structs and expression of
IL-1b. Representative fluo-
rescent images of monoclo-
nal antineutrophil antibody
(NIMP) and IL-1b staining
from MSC and EC con-
structs using mouse-specific
antibodies. (B) Colocaliza-
tion of monocyte-derived
cells and IL-6. Rep-
resentative fluorescent
images of mouse-specific
antibodies CD11b and IL-6
double staining for multinu-
cleated cells (10· magnifi-
cation, scale bar = 100 mm).
(C) Five sections from each
mouse and five images for
each section were used for
image quantification. The
number of neutrophils was
significantly higher in the
EC group (**p < 0.01, n = 6).
The number of IL-1b-
positive cells was lower in
the EC group (**p < 0.01,
n = 6). The number of
CD11b- and IL-6-positive
cells was decreased in the
EC group, but this was not
statistically significant. Col-
or images available online at
www.liebertpub.com/tea
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Discussion
In cell therapy, the release of inflammatory cytokines
facilitates vascularization and recruitment of leukocytes in
the first phase after implantation. If the balance between
pro- and anti-inflammatory cytokines is favorable, this leads
to tissue organization and regeneration.19,20 The aims of this
study were to evaluate and compare the initiation of an-
giogenesis and early inflammation after implantation of cell/
scaffold constructs using two different cell types. The cells
were grown under the same culture conditions before im-
plantation. The seeding efficiency of the two cell types in
the scaffold was similar. After implantation of the cells, host
tissue response was evaluated. The NOD/SCID mouse
model was chosen as it allows human cells to grow and
differentiate, and previous studies have shown that these
FIG. 5. Angiogenic properties of MSC
and EC were evaluated after 3 weeks of
implantation in vivo. (A) The proteome
profiler mouse angiogenesis kit was used to
access the relative levels of 53 angiogenesis-
related proteins in MSC and EC constructs;
highly regulated proteins were marked from
1 to 10. (B) Histogram profile of selected
proteins generated by quantifying the mean
spot pixel density from the arrays using
image software analysis. (C) CD31 im-
munostaining of blood vessels (red) at 20·
magnification (scale bar = 50 mm) and total
area fraction of CD31+ cells after 3 weeks of
implantation. The area fraction of vessel
formation was significantly higher in the EC
group (**p < 0.01). Nuclei were stained with
DAPI (blue). Color images available online
at www.liebertpub.com/tea
FIG. 4. Relative gene and protein expression of hypoxic markers after 3 weeks of implantation in vivo. Real-time RT–
PCR for mouse-specific genes (A) hypoxia-inducible factor 1-alpha (HIF-1a), (B) HIF-1b/aryl hydrocarbon receptor
nuclear translocator (ARNT), (C) nitric oxide synthase 2 (NOS2), and (D) mammalian target of rapamycin (mTOR). (E)
Relative protein expression of HIF-1a and HIF-1b in MSC and EC constructs.
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animals can produce monocyte-derived cells and neutro-
phils.21 This moderately immunocompromised murine
model thus also allows investigation of the early innate
immune response to implantation. Response of the im-
planted MSC and EC to hypoxia was investigated, as was
their effect on the local microenvironment, subsequent re-
cruitment of acute and chronic inflammatory cells, and es-
tablishment of blood vessels in the area of the implant. The
mouse-specific markers were used to evaluate the host re-
sponse toward the implanted cells.
MSC have been reported to express TLR that may play
a role in immune regulation. TLR priming of MSC results
in two active phenotypes, MSC1 and MSC2. TLR4-primed
MSC (MSC1) expresses proinflammatory cytokines, whereas
TLR3-primed MSC (MSC2) regulates anti-inflammatory
cytokines.22 TLR activation in MSC could produce inflam-
matory mediators, such as IL-1b, IL-6, IL-8/CXCL8, and
CCL5, resulting in recruitment of inflammatory cells.23 TLR
and its ligands may also induce the proliferation and differ-
entiation of MSC.24 TLR ligand activation on EC regulates
the expression of TLR1, TLR3, and TLR4 and downstream
production of IL-6.25 The superarray analysis in the present
study for the mouse TLR pathway demonstrated down-
regulation of the genes encoding TLR1, TLR2, TLR3, TLR4,
and TLR8 in the EC group compared with the MSC group
( p < 0.05). The downstream production of TLR was evaluated
by looking at mRNA expression of the genes encoding IL-1b,
IL-6, and IL-10. Macrophages are subdivided into M1 and
M2, according to their ability to produce different cytokines.
M1 releases proinflammatory cytokines in contrast to M2,
which releases anti-inflammatory cytokines.26 The mRNA
expression of genes encoding proinflammatory markers, such
as IL-1b and IL-6, was significantly downregulated in the EC
group compared with the MSC group ( p < 0.05), and EC
contributed to the anti-inflammatory effects via upregulated
mRNA expression of the IL-10 gene ( p < 0.01). These find-
ings suggest that EC can switch the cytokine expression of
macrophages to the anti-inflammatory M2 phenotype.
Copolymer scaffolds provide temporary support in tissue
engineering constructs as they degrade over time. A foreign-
body giant cell reaction mediates degradation of the scaffold
along with buildup of new extracellular matrix protein and
recruitment of granulocytes, MSC, and monocyte-derived
cells.27 Sung et al. found no significant difference in in-
flammatory cell recruitment by different copolymers after
2–4 weeks of implantation in vivo. Furthermore, they
showed that inflammatory cell recruitment had a positive
correlation with angiogenesis.28 Similarly, we demonstrated
the recruitment of inflammatory cells adjacent to the scaf-
fold after 3 weeks’ implantation. Neutrophils are the first
line of defense in acute inflammation. After 3 weeks’ im-
plantation, we observed that neutrophil transmigration to
the EC constructs was significantly higher than in MSC
constructs ( p < 0.01). Our previous study also found that
coculture of MSC with EC resulted in more leukocyte
transmigration to the construct via the TLR pathway.29 Fur-
thermore, IL-1b-positive monocyte-derived cells were de-
creased in the EC group relative to the MSC group ( p < 0.01),
while the number of IL-6- and CD11b-positive cells was
higher in the MSC group. Multinucleated giant cells were
found in proximity to the scaffold, aiding in degradation.
Neutrophils30 and CD11b-positive cells31 have been shown to
increase angiogenesis, and the differing inflammatory cell
recruitment seen between the experimental groups may also
have contributed to the difference in vascularization.
Tissue ischemia is one cause of failure of tissue-
engineered constructs. The inflamed microenvironment is
highly metabolic and has higher oxygen consumption,
leading to low oxygen tension. Additionally, hypoxia also
mediates acute and chronic inflammation. Hypoxia in the
surrounding environment activates the release of HIF, a
transcription factor for angiogenesis.32–34 The preimplanted
EC group showed upregulation of human hypoxia-related
genes. The paracrine effect of these cells could have influ-
enced the host microenvironment to promote angiogenesis.
The mRNA expression of the HIF-1a and HIF-1b genes was
significantly upregulated in the EC group, p < 0.05 and
p < 0.001, respectively. The upregulation in HIF genes
promotes angiogenesis. In addition, HIF-1a protein levels
were higher in the MSC group. The initiation of angiogen-
esis leads to higher oxygen saturation in the construct area,
which could have resulted in lower HIF-1a protein expres-
sion in EC constructs. However, it has been reported that
HIF-1b is less sensitive to change in oxygen tension.35 In
the present study, we found that mRNA expression and the
protein level of HIF-1b were upregulated in the EC group
compared to the MSC group.
NOS2/iNOS has also been reported as a hypoxia-inducible
gene. It regulates vascular homeostasis and inflammation
and may also promote HIF-1a stabilization and activate
downstream gene expression.36,37 We observed upregulation
of the NOS2 gene in the EC group compared with the MSC
group, promoting angiogenesis. The mRNA expression of
the gene encoding mTOR was higher in the EC constructs,
which also leads to vascularization of the constructs. The
mTOR pathway regulates cell proliferation, adhesion, mi-
gration, metabolism, and survival, and mTOR modulates
angiogenic factors by activating either HIF-1a or NOS2.
38
Proteome profiling was performed to compare the an-
giogenic factors released by EC and MSC constructs after
3 weeks’ implantation. Among all differentially regulated
proteins, osteopontin, nephroblastoma overexpressed (NOV),
and insulin-like growth factor-binding protein-3 (IGFBP-3)
highly upregulated in EC constructs. Osteopontin is a potent
angiogenic factor, which promotes proliferation, migration,
and capillary formation of EC.39 NOV is highly expressed
in SMC of the arterial vessel wall and supports cell adhe-
sion, migration, and survival of EC, resulting in neovascu-
larization.40 IGFBP-3 has diverse roles in angiogenesis. It
regulates proangiogenic molecules and induces capillary
formation in vivo.41 In 1999, Dawson et al. identified a serine
protease inhibitor, SERPIN F1, as an antiangiogenic factor.42
SERPIN F1 was increased following MSC implantation in
the present work. The release of proangiogenic proteins was
higher than antiangiogenic factors after implantation of EC,
which was reflected in the increased area of vessel formation.
Conclusions
Implantation of EC resulted in downregulation of TLR
and biomarkers associated with acute inflammation. Sig-
nificantly higher numbers of neutrophils were present after 3
weeks’ implantation, which was associated with hypoxia-
induced signaling. In addition, increased vascular ingrowth
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was found after implantation of EC. These findings suggest
that implantation of EC stimulates hypoxic signaling path-
ways, which leads to a prolonged acute inflammatory phase
compared with implantation of MSC. This promotes ingrowth
of vascular cells and establishment of the circulation.
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